<DOC>
	<DOCNO>NCT00466037</DOCNO>
	<brief_summary>Rituximab genetically engineer chimeric anti-CD20 monoclonal antibody selectively target CD20+ B cell induce transient depletion CD20+ mature B cell subpopulation.The objective study assess effect rituximab efficacy safety influenza virus vaccine patient rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>The Effect Rituximab Humoral Response Influenza Vaccine</brief_title>
	<detailed_description>The study population comprise RA patient treat conventional disease modify drug without rituximab . Split-virion inactivated vaccine contain 15 mcg hemagglutinin/dose B/Shanghai/361/02 ( SHAN ) , A/New Caledonia A/New Caledonia/ 20/99 ( NC ) ( H1N1 ) A/California/7/04 ( CAL ) ( H3N2 ) use . Disease activity assess number tender swollen joint , morning stiffness duration , evaluation pain day vaccination 4 week later . CD20 positive cell level assess rituximab treated patient . Hemagglutination inhibition ( HI ) antibody test response define &gt; 4-fold rise 4 week post vaccination seroconversion patient non-protective baseline level antibody ( &lt; 1/40 ) . Geometric mean titer ( GMT ) calculate subject . Results : The participant divide 3 group : RA ( n=29 , age 64±12 year ) , rituximab-treated RA ( n=14 , age 53±15 year ) healthy control ( n=21 , age 58±15 year ) . All baseline protective level HI antibody GMT similar . Four week vaccination , significant increase GMT NC California antigens subject , Shanghai antigen rituximab group . Similarly , percentage responder low Shanghai NC , significantly lower rituximab treat patient California antigen compare group . Parameters disease activity remain unchanged . Conclusion : Influenza virus vaccine generate humoral response RA study patient control . Although response significantly low among rituximab-treated patient ,</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients Rheumatoid Arthritis Age1885 Treatment Rituximab Disease modify drug Treatment anti TNF alpha Allergy egg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Rheumatoid</keyword>
	<keyword>rituximab</keyword>
	<keyword>influenza</keyword>
</DOC>